Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

121. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (Full text)

Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. For the majority no organic cause for their pain can be found on physical examination or investigation and although most children are likely managed by reassurance and simple measures, a large range of interventions have been recommended.To

2008 Cochrane PubMed

122. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (PubMed)

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. It is unclear whether the diagnosis includes children with different aetiologies for their pain. For the majority no organic cause for their pain can be found on physical examination or investigation. Although most children are likely managed

2008 Cochrane

123. Irritable bowel syndrome in adults: diagnosis and management

Irritable bowel syndrome in adults: diagnosis and management Irritable bowel syndrome in adults: Irritable bowel syndrome in adults: diagnosis and management diagnosis and management Clinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Irritable bowel syndrome in adults: diagnosis and management (CG61) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2008 National Institute for Health and Clinical Excellence - Clinical Guidelines

124. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. (Full text)

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude

2008 BMJ PubMed

125. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Ford A C, Talley N J, Velhuyzen van Zenten (...) S J, Vakil N B, Simel D L, Moayyedi P CRD summary This review assessed the ability of components of clinical history and physical examination (alone or in combination) to predict a diagnosis of irritable bowel syndrome (IBS) without full investigation of the lower GI tract. The authors' conclusion that individual symptoms and existing diagnostic criteria have only moderate accuracy was a reasonable interpretation of the limited data available. Authors' objectives To determine the accuracy

2008 DARE.

126. Effectiveness of probiotics in the treatment of irritable bowel syndrome

Effectiveness of probiotics in the treatment of irritable bowel syndrome Effectiveness of probiotics in the treatment of irritable bowel syndrome Effectiveness of probiotics in the treatment of irritable bowel syndrome Wilhelm S M, Brubaker C M, Varcak E A, Kale-Pradhan P B CRD summary The authors concluded that probiotics may improve symptoms in patients with irritable bowel syndrome, but that benefits were uncertain and further research was required. The authors’ cautious conclusion appeared (...) to reflect the evidence presented, but the limited search, lack of reporting of review methods and an incomplete validity assessment made it difficult to comment on reliability. Authors' objectives To evaluate the effectiveness of probiotics in providing global relief in patients with irritable bowel syndrome (IBS). Searching MEDLINE was searched from inception to October 2007. Search terms were reported. In addition, reference lists of articles were screened. Study selection Blinded, placebo-controlled

2008 DARE.

127. Meta-analysis of probiotics for the treatment of irritable bowel syndrome (Full text)

Meta-analysis of probiotics for the treatment of irritable bowel syndrome Meta-analysis of probiotics for the treatment of irritable bowel syndrome Meta-analysis of probiotics for the treatment of irritable bowel syndrome McFarland LV, Dublin S CRD summary This review concluded that probiotic use may be associated with improvement in irritable bowel syndrome symptoms compared to placebo, but these results should be interpreted with caution. This cautious conclusion accurately reflects (...) the nature of the evidence and the results of the review, and appears likely to be reliable. Authors' objectives To determine the overall efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). Searching MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and C databases and Google Scholar were searched. Reference lists of identified studies, reviews, commentaries, books and meeting abstracts were searched. Search terms were reported. Studies published in full

2008 DARE. PubMed

128. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials

Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Rahimi R, Nikfar S, Abdollahi M CRD summary The authors stated (...) that there was no statistically significant evidence that selective serotonin reuptake inhibitors (SSRIs) improved abdominal pain, bloating or irritable bowel syndrome (IBS) symptoms, although there was a trend for improvement in abdominal pain. In view of methodological limitations in the review, in particular the failure to adequately address heterogeneity, the conclusions may not be reliable. Authors' objectives To determine the efficacy of selective serotonin reuptake inhibitors (SSRIs) for irritable bowel syndrome (IBS

2008 DARE.

129. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Ford A C, Talley N J, Spiegel B M, Foxx-Orenstein A E, Schiller L, Quigley E M, Moayyedi P CRD (...) summary This review concluded that fibre, antispasmodics and peppermint oil are more effective than placebo for treating irritable bowel syndrome. Overall, although the review was generally well conducted, the authors' analyses should be interpreted with caution given their reliance on an often limited number of small and sometimes potentially quite different studies. Authors' objectives To compare the effectiveness of fibre, antispasmodics and peppermint oil with placebo or control for treating

2008 DARE.

130. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting (Full text)

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required.To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort (...) to placebo. Renzapride was well tolerated at all doses.This study confirms the gastrointestinal prokinetic effects of renzparide. The data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome.

2008 EvidenceUpdates PubMed

131. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

132. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome

The relationship between somatisation and outcome in patients with severe irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

133. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

134. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

135. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome

Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

136. Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. (PubMed)

Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. BACKGROUND & AIMS: Functional abdominal pain (FAP) and irritable bowel syndrome (IBS) are highly prevalent in childhood. A substantial proportion of patients continues to experience long-lasting symptoms. Gut-directed hypnotherapy (HT) has been shown to be highly effective in the treatment of adult IBS patients. We undertook a randomized controlled trial and compared clinical

2007 EvidenceUpdates

137. Hypnotherapy for treatment of irritable bowel syndrome. (PubMed)

Hypnotherapy for treatment of irritable bowel syndrome. Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder of unknown aetiology. Current pharmacological treatments have limited value. Hypnotherapy has been reported to have beneficial effects for IBS symptoms.To evaluate the efficacy of hypnotherapy for the treatment of irritable bowel syndrome.Published and unpublished randomised clinical trials and quasi-randomised clinical trials were identified through structured (...) for the treatment of irritable bowel syndrome with no treatment or another therapeutic intervention.All studies were evaluated for eligibility for inclusion. Included studies were assessed for quality and data were extracted independently by four authors. The primary outcome measure of interest was the overall bowel symptom severity score which combines abdominal pain, diarrhoea or constipation and bloating. Secondary outcomes included abdominal pain, diarrhoea, constipation, bloating, quality of life

2007 Cochrane

138. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. (PubMed)

Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. IBS is a complex disorder that encompasses a wide profile of symptoms. The symptoms of chronic constipation frequently resemble those of constipation-predominant IBS. Current drug treatments for irritable bowel syndrome (IBS) are of limited value. Many target specific symptoms only. Tegaserod, a 5HT(4) partial agonist, represents a novel mechanism of action in the treatment of IBS and chronic constipation.The (...) objective of this review was to evaluate the efficacy and tolerability of tegaserod for the treatment of IBS and chronic constipation in adults and adolescents aged 12 years and above.MEDLINE 1966-December 2006 and EMBASE 1980 to December 2006 were searched. The text and key words used included "tegaserod", "HTF 919", "irritable bowel", "constipation" and "colonic diseases, functional". The Cochrane Central Register of Controlled Trials, and the Inflammatory Bowel Disease Review Group Specialized Trials

2007 Cochrane

139. Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study

Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

140. Acupuncture for treatment of irritable bowel syndrome. (Full text)

Acupuncture for treatment of irritable bowel syndrome. Irritable bowel syndrome (IBS), a disorder of altered bowel habits associated with abdominal pain or discomfort. The pain, discomfort, and impairment from IBS often lead to healthcare medical consultation (Talley 1997) and workplace absenteeism, and associated economic costs (Leong 2003). A recent randomized controlled trial shows variable results but no clear evidence in support of acupuncture as an effective treatment for IBS (Fireman (...) 2001).The objective of this systematic review is to determine whether acupuncture is more effective than no treatment, more effective than 'sham' (placebo) acupuncture, and as effective as other interventions used to treat irritable bowel syndrome. Adverse events associated with acupuncture were also assessed.The following electronic bibliographic databases were searched irrespective of language, date of publication, and publication status: MEDLINE, the Cochrane Central Register of Controlled

2006 Cochrane PubMed